Pharmacogenetics of drug metabolizing enzymes in Brazilian populations

References

1. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11.10.1038/tpj.2012.45Search in Google Scholar

2. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013;138: 103–41.10.1016/j.pharmthera.2012.12.007Search in Google Scholar

3. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005;45:477–94.10.1146/annurev.pharmtox.45.120403.095821Search in Google Scholar

4. Dai DP, Xu RA, Hu LM, Wang SH, Geng PW, Yang JF, et al. CYP2C9 polymorphism analysis in Han Chinese populations: building the largest allele frequency database. Pharmacogenomics J 2014;14:85–92.10.1038/tpj.2013.2Search in Google Scholar

5. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23–37.10.1007/s00210-003-0832-2Search in Google Scholar

6. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity. J Toxicol Environ Health B Crit Rev 2009;12:362–88.10.1080/10937400903158359Search in Google Scholar

7. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383–91.10.1038/86882Search in Google Scholar

8. Lamba JK, Lin LS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54:1271–94.10.1016/S0169-409X(02)00066-2Search in Google Scholar

9. Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics 2005;15:625–31.10.1097/01.fpc.0000171516.84139.89Search in Google Scholar PubMed

10. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74–81.10.1152/physiolgenomics.00003.2007Search in Google Scholar PubMed

11. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005;573:180–94.10.1016/j.mrfmmm.2004.07.025Search in Google Scholar PubMed

12. Gervasini G, Benítez J, Carrillo JA. Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. Eur J Clin Pharmacol 2010;66:755–74.10.1007/s00228-010-0857-7Search in Google Scholar PubMed

13. Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT, Medina Pestana JO. Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009;41: 1441–55.10.1016/j.transproceed.2009.03.024Search in Google Scholar PubMed

14. Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2012;16:589–95.10.5588/ijtld.11.0377Search in Google Scholar PubMed

15. Du H, Chen X, Fang Y, Yan O, Xu H, Li L, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep 2013;40:3591–6.10.1007/s11033-012-2433-ySearch in Google Scholar PubMed

16. Bolt HM, Thier R. Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology. Curr Drug Metab 2006;7:613–28.10.2174/138920006778017786Search in Google Scholar PubMed

17. Di Pietro G, Magno LA, Rios-Santos F. Glutathione S-transferases: an overview in cancer research. Expert Opin Drug Metab Toxicol 2010;6:153–70.10.1517/17425250903427980Search in Google Scholar PubMed

18. Betonico GN, Abudd-Filho M, Goloni-Bertollo EM, Pavarino-Bertelli E. Pharmacogenetics of mycophenolate mofetil: a promising different approach to tailoring immunosuppression? J Nephrol 2008;21:503–9.Search in Google Scholar

19. Meyer UA. Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004;5:669–76.10.1038/nrg1428Search in Google Scholar PubMed

20. Sadee W, Wang D, Papp AC, Pinsonneault JK, Smith RM, Moyer RA, et al. Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clin Pharmacol Ther 2011;89:355–65.10.1038/clpt.2010.314Search in Google Scholar PubMed PubMed Central

21. Suarez-Kurtz G. Pharmacogenomics in admixed populations: the Brazilian pharmacogenetics/pharmacogenomics network–REFARGEN. Pharmacogenomics J 2004;4:347–8.10.1038/sj.tpj.6500287Search in Google Scholar PubMed

22. Suarez-Kurtz G, Perini JK, Bastos-Rodrigues L, Pena SD, Struchiner C. Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 2007;8:1299–306.10.2217/14622416.8.10.1299Search in Google Scholar PubMed

23. Suarez-Kurtz G, Genro JP, de Moraes MO, Ojopi EB, Pena SD, Perini JA, et al. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J 2012;12:267–76.10.1038/tpj.2010.89Search in Google Scholar PubMed

24. Sortica VA, Ojopi EB, Genro JP, Callegari-Jacques S, Ribeiro-Dos-Santos A, de Moraes MO, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol 2012;110:460–8.10.1111/j.1742-7843.2011.00838.xSearch in Google Scholar PubMed

25. Suarez-Kurtz G, Sortica VA, Vargens DD, Bruxel EM, Petzl-Erler ML, Petz-Erler ML, et al. Impact of population diversity on the prediction of 7-SNP NAT2 phenotypes using the tagSNP rs1495741 or paired SNPs. Pharmacogenet Genomics 2012;22:305–9.10.1097/FPC.0b013e3283519c7cSearch in Google Scholar PubMed

26. Suarez-Kurtz G, Pena SD, Hutz MH. Application of the F(ST) statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics 2012;13:771–7.10.2217/pgs.12.39Search in Google Scholar PubMed

27. Suarez-Kurtz G, Amorim A, Damasceno A, Hutz MH, de Moraes MO, Ojopi EB, et al. VKORC1 polymorphisms in Brazilians: comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics 2010;11:1257–67.10.2217/pgs.10.89Search in Google Scholar PubMed

28. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FS, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011;6:e17063.10.1371/journal.pone.0017063Search in Google Scholar PubMed PubMed Central

29. Suarez-Kurtz G, Vargens DD, Santoro AB, Hutz MH, de Moraes ME, Pena SD, et al. Global pharmacogenomics: distribution of CYP3A5 polymorphisms and phenotypes in the Brazilian population. PLoS One 2014;9:e83472.10.1371/journal.pone.0083472Search in Google Scholar PubMed PubMed Central

30. Durso DF, Bydlowski SP, Hutz MH, Suarez-Kurtz G, Magalhães TR, Junho Pena SD. Association of genetic variants with self-assessed color categories in Brazilians. PLoS One 2014;9:e83926.10.1371/journal.pone.0083926Search in Google Scholar PubMed PubMed Central

31. Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH. Pharmacogenomic diversity among Brazilians: influence of ancestry, self-reported color, and geographical origin. Front Pharmacol 2012;3:191.10.3389/fphar.2012.00191Search in Google Scholar PubMed PubMed Central

32. Suarez-Kurtz G, Pena SD. Pharmacogenomics in the Americas: the impact of genetic admixture. Curr Drug Targets 2006;7:1649–58.10.2174/138945006779025392Search in Google Scholar PubMed

33. Suarez-Kurtz G, Botton MR. Pharmacogenomics of warfarin in populations of African descent. Br J Clin Pharmacol 2013;75:334–46.10.1111/j.1365-2125.2012.04354.xSearch in Google Scholar PubMed PubMed Central

34. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 2004;279:23847–50.10.1074/jbc.R400004200Search in Google Scholar PubMed

35. Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 2013;288:12932–43.10.1074/jbc.M113.452953Search in Google Scholar PubMed PubMed Central

36. Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol 2004;67:1445–57.10.1016/j.bcp.2003.12.023Search in Google Scholar PubMed

37. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 2003;144:3382–98.10.1210/en.2003-0192Search in Google Scholar PubMed

38. Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 2009;11:481–94.10.1208/s12248-009-9127-ySearch in Google Scholar PubMed PubMed Central

39. Corchero J, Pimprale S, Kimura S, Gonzalez FJ. Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001;11:1–6.10.1097/00008571-200102000-00001Search in Google Scholar PubMed

40. Hiratsuka M. In vitro assessment of the allelic variants of cytochrome P450. Drug Metab Pharmacokinet 2012;27:68–84.10.2133/dmpk.DMPK-11-RV-090Search in Google Scholar

41. Shaik AP, Jamil K, Das P. CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis. Urol J 2009;6:78–86.Search in Google Scholar

42. Zhan P, Wang Q, Qian Q, Wei SZ, Yu LK. CYP1A1 MspI and exon7 gene polymorphisms and lung cancer risk: an updated meta-analysis and review. J Exp Clin Cancer Res 2011;30:99.10.1186/1756-9966-30-99Search in Google Scholar PubMed PubMed Central

43. Zhao Y, Chen ZX, Rewuti A, Ma YS, Wang XF, Xia Q, et al. Quantitative assessment of the influence of cytochrome P450 1A2 gene polymorphism and colorectal cancer risk. PLoS One 2013;8:e71481.10.1371/journal.pone.0071481Search in Google Scholar PubMed PubMed Central

44. Shimada N, Iwasaki M, Kasuga K, Yokoyama S, Onuma H, Nishimura H, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009;54:209–15.10.1038/jhg.2009.13Search in Google Scholar PubMed

45. dos Santos RA, Teixeira AC, Mayorano MB, Carrara HH, de Andrade J, Takahashi CS. Variability in estrogen-metabolizing genes and their association with genomic instability in untreated breast cancer patients and healthy women. J Biomed Biotechnol 2011;2011:571784.10.1155/2011/571784Search in Google Scholar PubMed PubMed Central

46. Lourenço GL, Silva EF, Rinck-Junior JA, Chone CT, Lima CS. CYP1A1, GSTM1 and GSTT1 polymorphisms, tobacco and alcohol status and risk of head and neck squamous cell carcinoma. Tumour Biol 2011;32:1209–15.10.1007/s13277-011-0224-zSearch in Google Scholar PubMed

47. Barbieri RB, Bufalo NE, Cunha LL, Assumpção LV, Maciel RM, Cerutti JM, et al. Genes of detoxification are important modulators of hereditary medullary thyroid carcinoma risk. Clin Endocrinol (Oxf) 2013;79:288–93.10.1111/cen.12136Search in Google Scholar PubMed

48. Abnet CC, Fagundes RB, Strickland PT, Kamangar F, Roth MJ, Taylor PR, et al. The influence of genetic polymorphisms in Ahr, CYP1A1, CYP1A2, CYP1B1, GST M1, GST T1 and UGT1A1 on urine 1-hydroxypyrene glucuronide concentrations in healthy subjects from Rio Grande do Sul, Brazil. Carcinogenesis 2007;28:112–7.10.1093/carcin/bgl131Search in Google Scholar PubMed

49. Cardoso-Filho C, Sarian LO, de Oliveira CB, da Silveira Bossi L, Lourenço GL, Lima CS, et al. Clinical effects of A4889G and T6235C polymorphisms in cytochrome P-450 CYP1A1 for breast cancer patients treated with tamoxifen: implications for tumor aggressiveness and patient survival. Cancer Chemother Pharmacol 2013;72:529–35.10.1007/s00280-013-2221-ySearch in Google Scholar PubMed

50. Almeida S, Zandoná MR, Franken N, Callegari-Jacques SM, Osório-Wender MC, Hutz MH. Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J 2005;5:346–51.10.1038/sj.tpj.6500329Search in Google Scholar PubMed

51. Kohlrausch FB, Severino-Gama C, Lobato MI, Belmonte-de-Abreu P, Carracedo A, Hutz MH. The CYP1A2 -163C>A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry Res 2013;209:242–5.10.1016/j.psychres.2013.02.030Search in Google Scholar PubMed

52. Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr 2011;69:153–8.10.1590/S0004-282X2011000200002Search in Google Scholar

53. Twardowschy CA, Werneck LC, Scola RH, Borgio JG, De Paola L, Silvado C. The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy. Seizure 2013;22:194–7.10.1016/j.seizure.2012.12.004Search in Google Scholar PubMed

54. Santos PC, Dinardo CL, Schettert IT, Soares RA, Kawabata-Yoshihara L, Bensenor IM, et al. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation. Eur J Clin Pharmacol 2013;69:789–97.10.1007/s00228-012-1404-5Search in Google Scholar PubMed

55. Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH. Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. Br J Clin Pharmacol 2011;72:442–50.10.1111/j.1365-2125.2011.03942.xSearch in Google Scholar PubMed PubMed Central

56. Orsi FA, Annichino Bizzacchi JM, de Paula EV, Ozelo MC, Langley MR, Weck KE. VKORC1 V66M mutation in African Brazilian patients resistant to oral anticoagulant therapy. Thromb Res 2010;126:e206–10.10.1016/j.thromres.2010.06.008Search in Google Scholar PubMed

57. Fuchshuber-Moraes F, Perini JA, Rosskopf D, Suarez-Kurtz G. Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. Eur J Clin Pharmacol 2009;65:789–93.10.1007/s00228-009-0651-6Search in Google Scholar PubMed

58. Perini JA, Struchiner CJ, Silva-Assunção E, Santana IS, Rangel F, Ojopi EB, et al. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008;84:722–8.10.1038/clpt.2008.166Search in Google Scholar PubMed

59. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur J Clin Pharmacol 2008;64:9–15.10.1007/s00228-007-0385-2Search in Google Scholar PubMed

60. Botton MR, Viola PP, Bandinelli E, Leiria TL, Rohde LE, Hutz MH. A new algorithm for weekly phenprocoumon dose variation in a Southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. Basic Clin Pharmacol Toxicol 2014;114:323–9.10.1111/bcpt.12172Search in Google Scholar PubMed

61. Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin Pharmacol Ther 2005;78:362–9.10.1016/j.clpt.2005.06.014Search in Google Scholar PubMed

62. Vianna-Jorge R, Perini JA, Rondinelli E, Suarez-Kurtz G. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. Clin Pharmacol Ther 2004;76:18–26.10.1016/j.clpt.2004.03.002Search in Google Scholar PubMed

63. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Callegari-Jacques SM, Gesteira A, et al. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenet Genomics 2008;18:599–609.10.1097/FPC.0b013e328301a763Search in Google Scholar PubMed

64. Forestiero FJ, Cecon L, Hirata MH, de Melo FF, Cardoso RF, Cerda A, et al. Relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver enzymes in Brazilian individuals under anti-tuberculosis drug therapy. Clin Chim Acta 2013;415:215–9.10.1016/j.cca.2012.10.030Search in Google Scholar PubMed

65. Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis 2013;17:499–504.10.5588/ijtld.12.0645Search in Google Scholar PubMed

66. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira AS, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011;106:716–24.10.1590/S0074-02762011000600011Search in Google Scholar PubMed

67. Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, et al. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clin Chim Acta 2013;421:157–63.10.1016/j.cca.2013.03.007Search in Google Scholar PubMed

68. Sprinz E, Bay MB, Lazzaretti RK, Jeffman MW, Mattevi VS. Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. HIV Med 2008;9:270–6.10.1111/j.1468-1293.2008.00558.xSearch in Google Scholar PubMed

69. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78:551–8.10.1016/j.clpt.2005.08.003Search in Google Scholar PubMed

70. Lopes LF, Piccoli FS, Paixão VA, Latorre MR, Camargo B, Simpson AJ, et al. Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL. Leuk Res 2004;28:1281–6.10.1016/j.leukres.2004.04.014Search in Google Scholar PubMed

71. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, et al. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients. Pharmacogenomics 2011;12:1293–303.10.2217/pgs.11.70Search in Google Scholar PubMed

72. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008;398:15–20.10.1016/j.cca.2008.07.032Search in Google Scholar PubMed

73. Estrela RC, Santoro AB, Barroso PF, Tuyama M, Suarez-Kurtz G. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin Pharmacol Ther 2008;84:205–7.10.1038/clpt.2008.12Search in Google Scholar PubMed

74. Moreira RP, Jorge AA, Gomes LG, Kaupert LC, Massud Filho J, Mendonca BB, et al. Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics (Sao Paulo) 2011;66:1361–6.10.1590/S1807-59322011000800009Search in Google Scholar PubMed PubMed Central

75. Perini JA, Struchiner CJ, Silva-Assunção E, Suarez-Kurtz G. Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin Pharmacol Ther 2010;87:417–20.10.1038/clpt.2009.307Search in Google Scholar PubMed

76. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013;58:395–8.10.1016/j.jhep.2012.08.018Search in Google Scholar PubMed

77. Khlifi R, Messaoud O, Rebai A, Hamza-Chaffai A. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers. Biomed Res Int 2013;2013:582768.10.1155/2013/582768Search in Google Scholar PubMed PubMed Central

78. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. A.A.T.S.H.O.A.T. Subcommittee An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935–52.10.1164/rccm.200510-1666STSearch in Google Scholar PubMed

79. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392: 1093–108.10.1007/s00216-008-2291-6Search in Google Scholar PubMed

80. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, et al. Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 2012;40:83–92.10.1124/dmd.111.042259Search in Google Scholar PubMed

81. Kalsotra A, Strobel HW. Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism. Pharmacol Ther 2006;112:589–611.10.1016/j.pharmthera.2006.03.008Search in Google Scholar PubMed

82. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease–implications for personalized medicine. Pharmacol Rev 2013;65:987–1009.10.1124/pr.112.007252Search in Google Scholar PubMed PubMed Central

83. Evrard A, Mbatchi L. Genetic polymorphisms of drug metabolizing enzymes and transporters: the long way from bench to bedside. Curr Top Med Chem 2012;12:1720–9.10.2174/156802612803531388Search in Google Scholar PubMed

84. Seki T, Tanaka T, Nakamura Y. Genomic structure and multiple single-nucleotide polymorphisms (SNPs) of the thiopurine S-methyltransferase (TPMT) gene. J Hum Genet 2000;45:299–302.10.1007/s100380070020Search in Google Scholar PubMed

85. Reis M, Santoro A, Suarez-Kurtz G. Thiopurine methyltransferase phenotypes and genotypes in Brazilians. Pharmacogenetics 2003;13:371–3.10.1097/00008571-200306000-00009Search in Google Scholar PubMed

86. Boson WL, Romano-Silva MA, Correa H, Falcão RP, Teixeira-Vidigal PV, De Marco L. Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J 2003;3:178–82.10.1038/sj.tpj.6500175Search in Google Scholar PubMed

87. Silva MR, de Oliveira BM, Viana MB, Murao M, Romanha AJ. Thiopurine S-methyltransferase (TPMT) gene polymorphism in Brazilian children with acute lymphoblastic leukemia: association with clinical and laboratory data. Ther Drug Monit 2008;30:700–4.10.1097/FTD.0b013e31818b0f31Search in Google Scholar PubMed

88. Gastal GR, Moreira S, Noble CF, Ferreira LE, França PH, Pinho M. Toxicity of azathioprine: why and when? Analysis of the prevalence of polymorphism in Joinville, SC, Brazil. Arq Gastroenterol 2012;49:130–4.10.1590/S0004-28032012000200007Search in Google Scholar PubMed

89. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673–81.10.1007/s00228-008-0484-8Search in Google Scholar PubMed

90. Costa GN, Magno LA, Santana CV, Konstantinovas C, Saito ST, Machado M, et al. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther 2012;16:241–50.10.1007/BF03262213Search in Google Scholar PubMed

91. Spinasse LB, Santos AR, Suffys PN, Muxfeldt ES, Salles GF. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics 2014;15:169–78.10.2217/pgs.13.202Search in Google Scholar PubMed

92. Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 2006;132:521–8.10.1007/s00432-006-0099-3Search in Google Scholar PubMed

93. Oliveira AL, Rodrigues FF, Santos RE, Aoki T, Rocha MN, Longui CA, et al. GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 2010;9:1045–53.10.4238/vol9-2gmr726Search in Google Scholar PubMed

94. Salinas-Souza C, Petrilli AS, de Toledo SR. Glutathione S-transferase polymorphisms in osteosarcoma patients. Pharmacogenet Genomics 2010;20:507–15.10.1097/FPC.0b013e32833caa45Search in Google Scholar PubMed

95. Silva DG, Belini Junior E, Torres LS, Ricci Júnior O, Lobo CC, Bonini-Domingos CR, et al. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. Blood Cells Mol Dis 2011;47:23–8.10.1016/j.bcmd.2011.03.004Search in Google Scholar PubMed

96. Silva MM, Da Fonseca CO, Moura-Neto R, Carvalho JF, Quirico-Santos T, Carvalho MG. Influence of GSTM1 and GSTT1 polymorphisms on the survival rate of patients with malignant glioma under perillyl alcohol-based therapy. Genet Mol Res 2013;12:1621–30.10.4238/2013.May.14.2Search in Google Scholar PubMed

97. Monteiro TP, El-Jaick KB, Jeovanio-Silva AL, Brasil PE, Costa MJ, Rolla VC, et al. The roles of GSTM1 and GSTT1 null genotypes and other predictors in anti-tuberculosis drug-induced liver injury. J Clin Pharm Ther 2012;37:712–8.10.1111/j.1365-2710.2012.01368.xSearch in Google Scholar PubMed

98. Vargens DD, Neves RR, Bulzico DA, Ojopi EB, Meirelles RM, Pessoa CN, et al. Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer. Pharmacogenet Genomics 2011;21:341–3.10.1097/FPC.0b013e3283448d19Search in Google Scholar PubMed

99. Smiderle L, Galvão AC, Fontana C, Wender MC, Agnes G, Giovenardi M, et al. Evaluation of UGT1A1 and SULT1A1 polymorphisms with lipid levels in women with different hormonal status. Gynecol Endocrinol 2011;27:20–6.10.3109/09513590.2010.493248Search in Google Scholar PubMed

100. Sim E, Walters K, Boukouvala S. Arylamine N-acetyltransferases: from structure to function. Drug Metab Rev 2008;40:479–510.10.1080/03602530802186603Search in Google Scholar PubMed

101. Huang YS, Su WJ, Huang YH, Chen CY, Chang FY, Lin HC, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007;47:128–34.10.1016/j.jhep.2007.02.009Search in Google Scholar PubMed

102. Gong QH, Cho LW, Huang T, Potter C, Gholami N, Basu NK, et al. Thirteen UDP-glucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics 2001;11:357–68.10.1097/00008571-200106000-00011Search in Google Scholar PubMed

103. Basu NK, Ciotti M, Hwang MS, Kole L, Mitra PS, Cho JW, et al. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem 2004;279:1429–41.10.1074/jbc.M306439200Search in Google Scholar PubMed

104. Lin LP, Cupples LA, Wilson PW, Heard-Costa N, O’Donnell CJ. Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet 2003;72:1029–34.10.1086/373964Search in Google Scholar PubMed PubMed Central

105. Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab Pharmacokinet 2013;28:83–92.10.2133/dmpk.DMPK-12-RV-096Search in Google Scholar

106. Ginsberg G, Guyton K, Johns D, Schimek J, Angle K, Sonawane B. Genetic polymorphism in metabolism and host defense enzymes: implications for human health risk assessment. Crit Rev Toxicol 2010;40:575–619.10.3109/10408441003742895Search in Google Scholar PubMed